Drugs / Fluzone® Intradermal
Fluzone® Intradermal
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT01518478 | Nov 2011 → Feb 2012 | atopic eczema | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT01946438 | Sep → Dec 2013 | influenza | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 4 | NCT01691339 | Sep → Nov 2012 | influenza | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Fluzone Intradermal | “Influenza Virus Vaccine: Fluzone® Intradermal 2012-2013 Formulation” NCT01691339 ↗ |
| Known as | Fluzone Intradermal (2012-2013 Formulation) | “Fluzone® Intradermal (2012-2013 Formulation)” NCT01691339 ↗ |
| Known as | Fluzone Intradermal, Influenza Virus Vaccine | “Fluzone® Intradermal, Influenza Virus Vaccine” NCT01946438 ↗ |
| Modality | Vaccine | “Fluzone® Intradermal trivalent vaccine” NCT01518478 ↗ |
| Route | Other | “for intradermal delivery of 0.1 mL via an ultra-fine micro-needle.” NCT01518478 ↗ |